Clinical Trial Update: C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) [Phase 1]

View source ↗

Summary

ClinicalTrials.gov entry updates the Phase 1 study of C7R-GD2.CART cells for relapsed or refractory GD2-positive cancers, including neuroblastoma and other tumo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Neuroblastoma
• Osteosarcoma
• Phyllodes Tumor of the Breast
• Rhabdomyosarcoma
• Uveal Melanoma

Drugs mentioned

• C7R-GD2.CART Cells (C7R-GD2 CAR-T cells)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Relapsed Neuroblastoma, Refractory Neuroblastoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING